Biotechnology companies disestablished in 2009

Wyeth Pharmaceuticals Inc. was a pharmaceutical company until it was purchased by Pfizer in 2009. The company was founded in Philadelphia, Pennsylvania, in 1860 as John Wyeth and Brother. Its headquarters moved to Collegeville, Pennsylvania, and Madison, New Jersey, before its headquarters were consolidated with Pfizer's in New York City after the 2009 merger.

Neurobiological Technologies, Inc. ("NTI") was a biotechnology company that was founded in 1987 by Enoch Callaway and John B. Stuppin to in-license and develop drugs primarily to treat neurological conditions; the company was dissolved in 2009 after the failure of its drug candidate ancrod in a Phase III trial for ischemic stroke.

Peptech Limited used to be an Australian biotechnology company listed on the Australian Stock Exchange (ASX). Peptech described its operations as "...an ASX-listed Australian biotechnology company dedicated to developing and providing antibody and peptide-based human therapeutic products for the treatment of diseases in the areas of cancer and inflammation and products for fertility control in animals." [1] The company changed its name to Arana Therapeutics in November 2007 and was subject of a successful takeover bid by Cephalon at the end of 2009.

Nventa Biopharmaceuticals Corporation was a Canadian-incorporated biopharmaceutical company headquartered in San Diego, California developing therapeutics for the treatment of viral infections and cancer, focusing on diseases caused by human papillomavirus (HPV). Nventa is currently the only company applying heat shock protein (Hsp) technology to target the over 20 million Americans already infected with HPV. Previously headquartered in Victoria, British Columbia, Canada, the company’s common stock traded on the Toronto Stock Exchange under the symbol: NVN.